Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05356182 · ClinicalTrials.gov registry record · NA

A Pilot and Feasibility Study of a Dietary Intervention With Low-protein Meals in Cancer Patients Receiving Immunotherapies

A NA study of Medical Oncology and Integrative Oncology, sponsored by State University of New York at Buffalo.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT05356182 is a NA study of Medical Oncology and Integrative Oncology that is actively recruiting participants, run by State University of New York at Buffalo. The registered enrollment target is 30 participants, below the 253-participant average among 3 other Medical Oncology trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05356182, a NA study of Medical Oncology and Integrative Oncology, is actively recruiting participants, sponsored by State University of New York at Buffalo.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The main idea of this study is that a low protein diet may alter the environment surrounding the tumor, enhancing the body's immune response leading to greater anticancer effects of treatment. This study intends to use a low-protein diet as a tool to enhance the immune response generated by immune check point inhibitor treatments.

Interventions

  • OTHER Diet

Study Locations (1)

New York

  • University at Buffalo / Great Lakes Cancer Care - Buffalo

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2022-05-04
Est. Completion 2027-02
Phase NA

What the Registry Record Tells You About NCT05356182

The ClinicalTrials.gov registry entry for NCT05356182 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 253-participant average among 3 other Medical Oncology trials with a reported enrollment target (88% lower). The listed sponsor is State University of New York at Buffalo, which has 243 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Medical Oncology appearing as the primary indexed condition, and to 1 intervention - of which Diet is the first listed.

NCT05356182 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT05356182 about?

NCT05356182 is a clinical study titled "A Pilot and Feasibility Study of a Dietary Intervention With Low-protein Meals in Cancer Patients Receiving Immunotherapies". The main idea of this study is that a low protein diet may alter the environment surrounding the tumor, enhancing the body's immune response leading to greater anticancer effects of treatment. This study intends to use a low-protein diet as a tool to enhance the immune response generated by immune c...

What is the current status of trial NCT05356182?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2022-05-04. Estimated completion is 2027-02.

What conditions does trial NCT05356182 study?

This clinical trial studies the following conditions: Medical Oncology, Integrative Oncology, Medical Nutrition Therapy.

What interventions are being tested in trial NCT05356182?

The interventions under investigation include: Diet (OTHER).

Who is sponsoring clinical trial NCT05356182?

This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05356182 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Medical Oncology

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.